![]() | Only 14 pages are availabe for public view |
Abstract Background: Anti-tuberculosis drugs are one of the most common causes of idiosyncratic hepatotoxicity. The antituberculosis drug-induced liver Anti TBDILI mechanism is related to cytochrome P4502E1 (CYP2E1). Genetic polymorphism of the CYP2E1 may affect the susceptibility to Anti TB -DILI Aim: Assessment of liver injury as well as identification of clinical risk factors for hepatotoxicity in patients receiving anti-Tuberculosis drugs and Assessment of frequency of CYP2E1 Polymorphisms gene and its association with Anti TB -DILI Materials and methods: Cohort longitudinal study was conducted on 75 patients receiving anti-tuberculosis drugs and CYP2E1 gene rs2031920 polymorphism identification was done. Results: Males were at a higher incidence of TB (54.7%), the mean age was 35.36± 14.05. The frequency of CYP2E1 polymorphisms was CT heterozygous (60%), CC homozygous (21%), and TT homozygous (12%). Among 75 patients ,19 patients developed (AT-DILI) (25.3%). they were categorized as mild, moderate, and severe representing 64.7%, 11.8%, 23.5% respectively. Among patients who developed AT-DILI, 12 patients were heterozygous CT genotype (63.2%), 5 patients were homozygous CC genotype (26.3%) and 2 patients were homozygous TT polymorphism (12 %). 73.7% were females (P = 0.004) and 36.8% were hypertensive liver injury was significantly lower among those taking a quadruple regimen with steroids. (P-value: 0.020) Conclusion: There was no association between CYP2E1 polymorphisms and anti TB DILI in this study with no statistically significant result was observed between grading of liver injury severity and CYP2E1 polymorphisms. |